SGLT2i DI Flashcards
SGLT2i MoA
Increases urinary glucose excretion
SGLT2i drugs
Canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro)
Canagliflozin brand name
Invokana
Dapagliflozin brand name
Farxiga
Empagliflozin brand name
Jardiance
Ertugliflozin brand name
Steglatro
Canagliflozin dosing
100-200mg PO QD
Dapagliflozin dosing
5-10mg PO QD
Empagliflozin dosing
10-25mg PO QD
Ertugliflozin dosing
5-15mg PO QD
SGLT2i side effects
Genital mycotic infections, UTI, ketoacidosis, weight loss, increased urination
Side effects specific to canagliflozin
lower limb amputation, fractures, hyperkalemia
Side effects specific to dapagliflozin
bladder cancer
SGLT2i drug interactions
hypotension if the patient is on an ACEi/ARB, diuretics, digoxin
SGLT2i CI
eGFR <30 mL/min
SGLT2i counseling
Take once a day at the same time (preferably in the morning), discuss yeast infections/UTIs in women, circumcision status, UTIs, and penile discharge in men
SGLT2i clinical pearls
High A1C lowering, no hypoglycemia, weight loss
SGLT2is with CKD benefit
Canagliflozin and dapagliflozin
SGLT2is with HF benefit
Empagliflozin and dapagliflozin
SGLT2is with ASCVD benefit
Canagliflozin, empagliflozin, dapagliflozin
SGLT2i considerations
Gangrene, DKA, amputations, increased LDL
SGLT2i monitoring
FBG/PPG, UTI, yeast infection, BP
SGLT2i peak effect
4-6 weeks
ADA guidelines on SGLT2is
Use if ASCVD risk is high, CKD, HF, to minimize hypoglycemia, weight loss
AACE guidelines on SGLT2is
Third-line option after metformin and GLP-1 RA
